Thomas Richard Kassberg

CIK: 0001303811

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (16.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)1 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

PASG

Passage BIO, Inc.

Director

RARE

Ultragenyx Pharmaceutical Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

PASG
Passage BIO, Inc.
May 19, 2026
Award(A)
Director Stock Option (right to buy)
Direct
10.5K shares-
PASG
Passage BIO, Inc.
May 28, 2025
Award(A)
Director Stock Option (right to buy)
Direct
143.8K shares-
RARE
Ultragenyx Pharmaceutical Inc.
Mar 3, 2025
Sale(S)
Direct
6K shares at avg. $42.10$254K
RARE
Ultragenyx Pharmaceutical Inc.
Mar 3, 2025
Tax Payment(F)
Direct
508 shares at avg. $42.92$22K
RARE
Ultragenyx Pharmaceutical Inc.
Mar 1, 2025
Award(A)
Direct
18.4K shares-
PASG
Passage BIO, Inc.
Sep 30, 2024
Award(A)
Employee Stock Option (right to buy)
Direct
174.1K shares-

		Type	Shares	Price		Ownership
May 19, 2026	PASG Passage BIO, Inc.	Award(A) Director Stock Option (right to buy)	10,539	-	-	Direct
May 28, 2025	PASG Passage BIO, Inc.	Award(A) Director Stock Option (right to buy)	143,789	-	-	Direct
Mar 3, 2025	RARE Ultragenyx Pharmaceutical Inc.	Sale(S)	6,028	$42.10	$253,779	Direct
Mar 3, 2025	RARE Ultragenyx Pharmaceutical Inc.	Tax Payment(F)	508	$42.92	$21,803	Direct
Mar 1, 2025	RARE Ultragenyx Pharmaceutical Inc.	Award(A)	18,443	-	-	Direct
Sep 30, 2024	PASG Passage BIO, Inc.	Award(A) Employee Stock Option (right to buy)	174,139	-	-	Direct

1-6 of 6 transactions

About Kassberg Thomas Richard

Kassberg Thomas Richard (SEC CIK 0001303811) files insider reports with the SEC as Director of Passage BIO, Inc. (PASG) and CBO & EVP of Ultragenyx Pharmaceutical Inc. (RARE).

Signal8 holds 5 ownership filings by Kassberg Thomas Richard (1 Form 3, 4 Form 4), filed between Oct 2, 2024 and May 21, 2026. Those filings report 6 transactions, from Sep 30, 2024 to May 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Kassberg Thomas Richard's filings is in PHILADELPHIA, PA.

Recent filings by Kassberg Thomas Richard

May 19, 2026: Grant or award of PASG derivative securities (Form 4, code A).
May 28, 2025: Grant or award of PASG derivative securities (Form 4, code A).
Mar 3, 2025: Open-market sale of RARE shares (Form 4, code S).
Mar 3, 2025: Tax withholding of RARE shares (Form 4, code F).
Mar 1, 2025: Grant or award of RARE shares (Form 4, code A).

Other insiders filing for Passage BIO, Inc. (PASG)

Lynx1 Capital Management LP, 10% Owner
Sondhi Dolan, Director
Porter Derrell, Director
Kapadia Sandip, Director
GOWEN MAXINE, Director
Countouriotis Athena, Director

How to read Form 4 transaction codes